While three HDAC inhibitors (HDACi's) have been approved by the FDA for various hematologic malignancies, they are associated with several side effects; it is speculated that this is due, at least in part, to their pan‐HDAC inhibitory activities (Ho et al. 2020). Here, HDAC9 is linked to hematologic disorder.